MCID: ALP048
MIFTS: 31

Alopecia Totalis

Categories: Rare diseases, Skin diseases

Aliases & Classifications for Alopecia Totalis

MalaCards integrated aliases for Alopecia Totalis:

Name: Alopecia Totalis 20 58 70
Loss of All Scalp Hair 20

Characteristics:

Orphanet epidemiological data:

58
alopecia totalis
Age of onset: All ages; Age of death: normal life expectancy;

Classifications:

Orphanet: 58  
Rare skin diseases


External Ids:

ICD10 32 L63.0
ICD10 via Orphanet 33 L63.0
UMLS via Orphanet 71 C0263504
Orphanet 58 ORPHA700
SNOMED-CT via HPO 68 278040002 298000004 56317004
UMLS 70 C0263504

Summaries for Alopecia Totalis

GARD : 20 Alopecia totalis (AT) is a condition characterized by the complete loss of hair on the scalp. It is an advanced form of alopecia areata a condition that causes round patches of hair loss. Although the exact cause of AT is unknown, it is thought to be an autoimmune condition in which the immune system mistakenly attacks the hair follicles. Roughly 20% of affected people have a family member with alopecia, suggesting that genetic factors may contribute to the development of AT. There is currently no cure for AT, but sometimes hair regrowth occurs on it's own, even after many years.

MalaCards based summary : Alopecia Totalis, also known as loss of all scalp hair, is related to hypertrophic cardiomyopathy and alopecia areata. An important gene associated with Alopecia Totalis is UQCRFS1 (Ubiquinol-Cytochrome C Reductase, Rieske Iron-Sulfur Polypeptide 1). The drugs Methylprednisolone and Methylprednisolone hemisuccinate have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, thymus and monocytes, and related phenotypes are alopecia of scalp and alopecia

Wikipedia : 73 Alopecia totalis is the loss of all skull and facial hair. Its causes are unclear, but believed to be... more...

Related Diseases for Alopecia Totalis

Diseases related to Alopecia Totalis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Related Disease Score Top Affiliating Genes
1 hypertrophic cardiomyopathy 29.1 UQCRFS1 TMPO
2 alopecia areata 11.4
3 mitochondrial complex iii deficiency, nuclear type 10 11.1
4 woodhouse-sakati syndrome 11.1
5 t-cell immunodeficiency, congenital alopecia, and nail dystrophy 11.1
6 alopecia 10.9
7 alopecia universalis congenita 10.6
8 vitiligo-associated multiple autoimmune disease susceptibility 6 10.2
9 vitiligo-associated multiple autoimmune disease susceptibility 1 10.2
10 dermatitis 10.2
11 autoimmune disease 10.1
12 dermatitis, atopic 10.1
13 diffuse alopecia areata 10.1
14 hypogonadism 10.1
15 atrial standstill 1 9.9
16 hashimoto thyroiditis 9.9
17 chromosome 18p deletion syndrome 9.9
18 ige responsiveness, atopic 9.9
19 myositis 9.9
20 myasthenia gravis 9.9
21 aplastic anemia 9.9
22 trichotillomania 9.9
23 nail disorder, nonsyndromic congenital, 9 9.9
24 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 9.9
25 ptosis 9.9
26 rapidly involuting congenital hemangioma 9.9
27 mitochondrial complex iii deficiency 9.9
28 hand, foot and mouth disease 9.9
29 common variable immunodeficiency 9.9
30 pancytopenia 9.9
31 gout 9.9
32 polyneuropathy 9.9
33 autoimmune polyendocrine syndrome 9.9
34 acute retrobulbar neuritis 9.9
35 hypothyroidism 9.9
36 ichthyosis 9.9
37 neuritis 9.9
38 impotence 9.9
39 hepatitis c 9.9
40 amelogenesis imperfecta 9.9
41 irritant dermatitis 9.9
42 contact dermatitis 9.9
43 allergic contact dermatitis 9.9
44 neurodermatitis 9.9
45 lactic acidosis 9.9
46 pseudohermaphroditism 9.9
47 mouth disease 9.9
48 myopathy 9.9
49 pustulosis of palm and sole 9.9
50 folliculitis 9.9

Graphical network of the top 20 diseases related to Alopecia Totalis:



Diseases related to Alopecia Totalis

Symptoms & Phenotypes for Alopecia Totalis

Human phenotypes related to Alopecia Totalis:

31 58
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 alopecia of scalp 31 hallmark (90%) HP:0002293
2 alopecia 58 Very frequent (99-80%)
3 scalp hair loss 58 Very frequent (99-80%)

Drugs & Therapeutics for Alopecia Totalis

Drugs for Alopecia Totalis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 33)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
2
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
3 Orange Approved Phase 4
4
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
5
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
6
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
7
Hydroxychloroquine Approved Phase 4 118-42-3 3652
8
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
9 Antirheumatic Agents Phase 4
10 Methylprednisolone Acetate Phase 4
11 Gastrointestinal Agents Phase 4
12 Hormones Phase 4
13 Antiemetics Phase 4
14 Antineoplastic Agents, Hormonal Phase 4
15 Neuroprotective Agents Phase 4
16 Hormone Antagonists Phase 4
17 Anti-Inflammatory Agents Phase 4
18 Protective Agents Phase 4
19 glucocorticoids Phase 4
20 Antiparasitic Agents Phase 4
21 Antimalarials Phase 4
22 Anti-Infective Agents Phase 4
23 Antiprotozoal Agents Phase 4
24
Acetylcholine Approved, Investigational Phase 2, Phase 3 51-84-3 187
25 Neurotransmitter Agents Phase 2, Phase 3
26 abobotulinumtoxinA Phase 2, Phase 3
27 Cholinergic Agents Phase 2, Phase 3
28 Botulinum Toxins, Type A Phase 2, Phase 3
29 Botulinum Toxins Phase 2, Phase 3
30
tannic acid Approved Phase 2 1401-55-4
31
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
32 Janus Kinase Inhibitors Phase 2
33 Pharmaceutical Solutions Phase 2

Interventional clinical trials:

(show all 12)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata Completed NCT01167946 Phase 4 methylprednisolone sodium succinate;methylprednisolone sodium succinate;methylprednisolone sodium succinate
2 Open Label Study of Hydroxychloroquine for Alopecia Areata, Alopecia Totalis Completed NCT00176982 Phase 4 Hydroxychloroquine
3 The Randomized Double-blind Placebo-controlled Trial of Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecia Totalis and Alopecia Universalis Completed NCT00997815 Phase 2, Phase 3 Botulinum toxin A;Normal saline injection
4 Defining Reversal of Alopecia Areata (AA) Phenotype With Dupilumab in Patients With and Without Associated Atopic Dermatitis (AD) Completed NCT03359356 Phase 2 Dupilumab;Placebos
5 A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-501 Oral Suspension Compared to Placebo in Adult Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis Completed NCT03594227 Phase 2 ATI-501 400mg BID (Low dose);ATI-501 600mg BID (Mid dose);ATI-501 800mg BID (High dose);Placebo
6 An Open-Label Pilot Study of the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily in Adult Subjects With Eyebrow Loss Due to Alopecia Areata, Alopecia Universalis or Alopecia Totalis Completed NCT03551821 Phase 2 ATI-50002
7 A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ATI-50002 Topical Solution Administered Twice-Daily for 28 Days in Adult Subjects With Alopecia Universalis and Alopecia Totalis With a 12-Month Long-Term Open-Label Extension Completed NCT03315689 Phase 2 Vehicle;ATI-50002
8 A PHASE 2a, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY INVESTIGATING THE SAFETY OF RITLECITINIB (PF-06651600) IN ADULT PARTICIPANTS WITH ALOPECIA AREATA Recruiting NCT04517864 Phase 2 PF-06651600;Placebo
9 An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata Terminated NCT02553330 Phase 2 Placebo Cream;Ruxolitinib Phosphate Cream
10 Open-Label Study of ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT) Terminated NCT03759340 Phase 2 ATI 502 0.46% Topical Solution
11 Efalizumab in the Treatment of Alopecia Totalis/Universalis in Young Adults, Phase II Withdrawn NCT00746980 Phase 2 efalizumab
12 A Randomized, Double Blind, Placebo Controlled Clinical Trial to Evaluate the Efficacy of Abatacept Costimulatory Blockade in the Treatment of Alopecia Totalis/Universalis Withdrawn NCT01314495 Phase 2 Abatacept;Inactive infusion

Search NIH Clinical Center for Alopecia Totalis

Genetic Tests for Alopecia Totalis

Anatomical Context for Alopecia Totalis

MalaCards organs/tissues related to Alopecia Totalis:

40
Bone Marrow, Thymus, Monocytes, Nk Cells, T Cells, Bone

Publications for Alopecia Totalis

Articles related to Alopecia Totalis:

(show top 50) (show all 299)
# Title Authors PMID Year
1
Successful Treatment of Long Standing Alopecia Totalis with Intralesional Methotrexate. 61
33780590 2021
2
Alopecia totalis following hand-foot-and-mouth disease. 61
33650159 2021
3
Correlation between serum granulysin level and clinical activity in patients with alopecia areata before and after tofacitinib therapy. 61
32808476 2021
4
ccl13 is upregulated in alopecia areata lesions and is correlated with disease severity. 61
33523560 2021
5
Therapeutic management in pediatric alopecia areata: a systematic review. 61
33630354 2021
6
Squaric acid dibutyl ester for the treatment of alopecia areata: A retrospective evaluation. 61
33377267 2021
7
Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options. 61
33386567 2021
8
Demographic and Clinical Features of 1,641 Patients with Alopecia Areata, Alopecia Totalis, and Alopecia Universalis: A Single-Center Retrospective Study. 61
33614711 2021
9
Discoid Lupus Erythematosus in a Patient With Alopecia Totalis. 61
32926840 2021
10
Microblading and the Science Behind it. 61
33768017 2021
11
Assessment of treatment efficacy of diphenylcyclopropenone (DPCP) for alopecia areata 61
31655499 2020
12
Validation of Case Identification for Alopecia Areata Using International Classification of Diseases Coding. 61
33531746 2020
13
Topical immunotherapy in combination with anthralin in the treatment of refractory alopecia areata. 61
32621407 2020
14
A case report of alopecia totalis associated with permanent hair dye use. 61
32875023 2020
15
[Successful treatment of alopecia totalis with tofacitinib in a Danish patient]. 61
32829749 2020
16
Association of alopecia with self-esteem in children and adolescents. 61
32829314 2020
17
Rapid hair regrowth induced by dupilumab in a patient affected by alopecia totalis of 28 years' duration: Clinical and dermoscopic features. 61
32406158 2020
18
Cyclosporine With and Without Systemic Corticosteroids in Treatment of Alopecia Areata: A Systematic Review. 61
32270396 2020
19
Pediatric alopecia areata. 61
32351186 2020
20
Delay in the Diagnosis of APECED: A Case Report and Review of Literature from Iran. 61
31588815 2020
21
Successful treatment of alopecia totalis with ruxolitinib in a preadolescent patient. 61
32258291 2020
22
Alopecia totalis and universalis long-term outcomes: a review. 61
31593606 2020
23
Hereditary vitamin D-resistant rickets: a report of four cases with two novel variants in the VDR gene and successful use of intermittent intravenous calcium via a peripheral route. 61
32049653 2020
24
Epidemiology of alopecia areata, ophiasis, totalis, and universalis: A systematic review and meta-analysis. 61
31437543 2020
25
Bi-Allelic UQCRFS1 Variants Are Associated with Mitochondrial Complex III Deficiency, Cardiomyopathy, and Alopecia Totalis. 61
31883641 2020
26
A Large Cross-Sectional Survey Study of the Prevalence of Alopecia Areata in the United States. 61
32280257 2020
27
Steroid-resistant alopecia totalis in a child successfully treated with oral apremilast and platelet-rich plasma therapy. 61
31495982 2019
28
Patients with alopecia areata show signs of insulin resistance. 61
31089876 2019
29
Are Preferred Scalp Locations for Alopecia Areata Patches a Clue to Neuronal Etiology? 61
31559251 2019
30
Treatment of alopecia areata with nonablative fractional laser combined with topical minoxidil. 61
31245963 2019
31
Alopecia areata in Tunisia: epidemio-clinical aspects and comorbid conditions. A prospective study of 204 cases. 61
30677128 2019
32
Treatment of alopecia areata: An Australian expert consensus statement. 61
30411329 2019
33
Central diabetes insipidus in a patient with NFKB2 mutation: Expanding the endocrine phenotype in DAVID syndrome. 61
31150062 2019
34
All-Cause and Cause-Specific Mortality Risks Associated With Alopecia Areata: A Korean Nationwide Population-Based Study. 61
31141109 2019
35
Alopecia areata: A multifactorial autoimmune condition. 61
30558963 2019
36
Systemic treatments for alopecia areata: A systematic review. 61
30191561 2019
37
The Role of Tofacitinib in the Management of Alopecia Totalis. 61
31198601 2019
38
Familial Vitamin D-dependent rickets Type 2A: A report of two cases with alopecia and oral manifestations. 61
30967742 2019
39
Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study. 61
30566941 2019
40
Comparison of the Treatment Outcome of Oral Tofacitinib with Other Conventional Therapies in Refractory Alopecia Totalis and Universalis: A Retrospective Study. 61
30281139 2019
41
Serum Interleukin-15 is a Marker of Alopecia Areata Severity. 61
30820130 2019
42
Vitamin D supplementation for the prevention or depletion of side effects of therapy with alemtuzumab in multiple sclerosis. 61
31371976 2019
43
Alopecia areata and overt thyroid diseases: A nationwide population-based study. 61
30222206 2018
44
Efficacy of diphenylcyclopropenone in alopecia areata: a comparison of two treatment regimens. 61
30618524 2018
45
Hair Regrowth in a Patient With Long-standing Alopecia Totalis and Atopic Dermatitis Treated With Dupilumab. 61
30304403 2018
46
Risk of sun-induced skin cancers in patients with alopecia areata, alopecia totalis and alopecia universalis. 61
29679494 2018
47
Hair Regrowth Outcomes of Contact Immunotherapy for Patients With Alopecia Areata: A Systematic Review and Meta-analysis. 61
30073292 2018
48
Is methotrexate an effective and safe treatment for maintaining hair regrowth in people with alopecia totalis? A Critically Appraised Topic. 61
29777625 2018
49
Cancer risk by the subtype of alopecia. 61
29950587 2018
50
Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis. 61
29754888 2018

Variations for Alopecia Totalis

Expression for Alopecia Totalis

Search GEO for disease gene expression data for Alopecia Totalis.

Pathways for Alopecia Totalis

GO Terms for Alopecia Totalis

Sources for Alopecia Totalis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....